BACKGROUND & AIMS: Therapeutic options are limited for patients with recurrent acute pancreatitis who have intractable symptoms despite maximal endoscopic and medical treatment, but equivocal or no morphologic or functional evidence of chronic pancreatitis. We performed a prospective observational cohort study to determine the efficacy of total pancreatectomy with islet autotransplantation (TPIAT) for these patients. METHODS: We collected data from all patients undergoing TPIAT at the University of Minnesota from 2007 through 2013; 49 patients (42 female; mean age, 32.8 ± 7.8 years) had a diagnosis of recurrent acute pancreatitis not provoked by intervention, with negative or equivocal findings from nondiagnostic imaging or pancreatic function tests for chronic pancreatitis, and intractable pain between episodes. Data on insulin use, narcotic requirements, pain scores, and health-related quality of life were collected before TPIAT; 3 months, 6 months, and 1 year afterward; and then yearly. RESULTS: All 49 patients studied required narcotics before TPIAT (45 daily users and 4 intermittent users); 2 had insulin-treated diabetes. At 1 year after TPIAT, 22 out of 48 patients (46%) reported no use of narcotic pain medications (P < .001 vs baseline). Health-related quality of life score, measured by the physical and mental component summary score, increased by approximately 1 standard deviation from the population mean (P < .001 for the physical component summary; P = .019 for the mental component summary). At 1 year after TPIAT, 21 out of 48 patients (45%) were insulin independent; their mean percent glycosylated hemoglobin A1c at 1 year after TPIAT was 6.0% ± 0.9% (5.2% ± 0.6% pre-TPIAT). CONCLUSIONS: Patients with recurrent acute pancreatitis but lacking clear chronic pancreatitis benefit from TPIAT, with outcomes similar to those previously described for patients with chronic pancreatitis (improved quality of life and reduced narcotic use). For these patients who have otherwise limited surgical treatment options, TPIAT can be considered when medical and endoscopic therapies have failed.
BACKGROUND & AIMS: Therapeutic options are limited for patients with recurrent acute pancreatitis who have intractable symptoms despite maximal endoscopic and medical treatment, but equivocal or no morphologic or functional evidence of chronic pancreatitis. We performed a prospective observational cohort study to determine the efficacy of total pancreatectomy with islet autotransplantation (TPIAT) for these patients. METHODS: We collected data from all patients undergoing TPIAT at the University of Minnesota from 2007 through 2013; 49 patients (42 female; mean age, 32.8 ± 7.8 years) had a diagnosis of recurrent acute pancreatitis not provoked by intervention, with negative or equivocal findings from nondiagnostic imaging or pancreatic function tests for chronic pancreatitis, and intractable pain between episodes. Data on insulin use, narcotic requirements, pain scores, and health-related quality of life were collected before TPIAT; 3 months, 6 months, and 1 year afterward; and then yearly. RESULTS: All 49 patients studied required narcotics before TPIAT (45 daily users and 4 intermittent users); 2 had insulin-treated diabetes. At 1 year after TPIAT, 22 out of 48 patients (46%) reported no use of narcotic pain medications (P < .001 vs baseline). Health-related quality of life score, measured by the physical and mental component summary score, increased by approximately 1 standard deviation from the population mean (P < .001 for the physical component summary; P = .019 for the mental component summary). At 1 year after TPIAT, 21 out of 48 patients (45%) were insulin independent; their mean percent glycosylated hemoglobin A1c at 1 year after TPIAT was 6.0% ± 0.9% (5.2% ± 0.6% pre-TPIAT). CONCLUSIONS:Patients with recurrent acute pancreatitis but lacking clear chronic pancreatitis benefit from TPIAT, with outcomes similar to those previously described for patients with chronic pancreatitis (improved quality of life and reduced narcotic use). For these patients who have otherwise limited surgical treatment options, TPIAT can be considered when medical and endoscopic therapies have failed.
Authors: Marc F Catalano; Anand Sahai; Michael Levy; Joseph Romagnuolo; Maurits Wiersema; William Brugge; Martin Freeman; Kenji Yamao; Marcia Canto; Lyndon V Hernandez Journal: Gastrointest Endosc Date: 2009-02-24 Impact factor: 9.427
Authors: Gregory C Wilson; Jeffrey M Sutton; Daniel E Abbott; Milton T Smith; Andrew M Lowy; Jeffrey B Matthews; Horacio L R Rilo; Nathan Schmulewitz; Marzieh Salehi; Kyuran Choe; John Brunner; Dennis J Hanseman; Jeffrey J Sussman; Michael J Edwards; Syed A Ahmad Journal: Ann Surg Date: 2014-10 Impact factor: 12.969
Authors: Syed A Ahmad; Andrew M Lowy; Curtis J Wray; David D'Alessio; Kywran A Choe; Laura E James; Andreas Gelrud; Jeffrey B Matthews; Horacio L R Rilo Journal: J Am Coll Surg Date: 2005-09-23 Impact factor: 6.113
Authors: David E R Sutherland; David M Radosevich; Melena D Bellin; Bernard J Hering; Gregory J Beilman; Ty B Dunn; Srinath Chinnakotla; Selwyn M Vickers; Barbara Bland; A N Balamurugan; Martin L Freeman; Timothy L Pruett Journal: J Am Coll Surg Date: 2012-03-06 Impact factor: 6.113
Authors: Darwin L Conwell; Linda S Lee; Dhiraj Yadav; Daniel S Longnecker; Frank H Miller; Koenraad J Mortele; Michael J Levy; Richard Kwon; John G Lieb; Tyler Stevens; Phillip P Toskes; Timothy B Gardner; Andres Gelrud; Bechien U Wu; Christopher E Forsmark; Santhi S Vege Journal: Pancreas Date: 2014-11 Impact factor: 3.327
Authors: Heather A Clayton; Joanna E Davies; Cris A Pollard; Steve A White; Patrick P Musto; Ashley R Dennison Journal: Transplantation Date: 2003-07-15 Impact factor: 4.939
Authors: Giuseppe Garcea; Cristina A Pollard; Severine Illouz; M'Balu Webb; Matthew S Metcalfe; Ashley R Dennison Journal: Pancreas Date: 2013-03 Impact factor: 3.327
Authors: Luis F Lara; Melena D Bellin; Emmanuel Ugbarugba; Jaimie D Nathan; Piotr Witkowski; Martin Wijkstrom; Jennifer L Steel; Kerrington D Smith; Vikesh K Singh; Sarah J Schwarzenberg; Timothy L Pruett; Bashoo Naziruddin; Leslie Long-Simpson; Varvara A Kirchner; Timothy B Gardner; Martin L Freeman; Ty B Dunn; Srinath Chinnakotla; Gregory J Beilman; David B Adams; Katherine A Morgan; Maisam A Abu-El-Haija; Syed Ahmad; Andrew M Posselt; Michael G Hughes; Darwin L Conwell Journal: Pancreas Date: 2019-10 Impact factor: 3.327
Authors: Varvara A Kirchner; Ty B Dunn; Gregory J Beilman; Srinath Chinnakotla; Timothy L Pruett; Joshua J Wilhelm; Sarah J Schwarzenberg; Martin L Freeman; Melena D Bellin Journal: Curr Treat Options Gastroenterol Date: 2017-12
Authors: Gregory A Coté; Dhiraj Yadav; Judah A Abberbock; David C Whitcomb; Stuart Sherman; Bimaljit S Sandhu; Michelle A Anderson; Michele D Lewis; Samer Alkaade; Vikesh K Singh; John Baillie; Peter A Banks; Darwin Conwell; Nalini M Guda; Thiruvengadam Muniraj; Gong Tang; Randall Brand; Andres Gelrud; Stephen T Amann; Christopher E Forsmark; Mel C Wilcox; Adam Slivka; Timothy B Gardner Journal: Am J Gastroenterol Date: 2018-06-05 Impact factor: 10.864
Authors: Chang-Il Kwon; Jae Hee Cho; Sung Hoon Choi; Kwang Hyun Ko; Temel Tirkes; Mark A Gromski; Glen A Lehman Journal: Korean J Intern Med Date: 2019-02-25 Impact factor: 2.884
Authors: Luis F Lara; Solvejg Wastvedt; James S Hodges; Piotr Witkowski; Martin Wijkstrom; R Matthew Walsh; Vikesh K Singh; Sarah J Schwarzenberg; Timothy L Pruett; Andrew Posselt; Bashoo Naziruddin; Jaimie D Nathan; Katherine A Morgan; Rebecca Mitchell; Varvara A Kirchner; SriPrakash L Mokshagundam; Betul Hatipoglu; Timothy B Gardner; Martin L Freeman; Srinath Chinnakotla; Gregory J Beilman; Maisam Abu-El-Haija; Darwin L Conwell; Melena D Bellin Journal: Pancreas Date: 2021-07-01 Impact factor: 3.243
Authors: Kendall R McEachron; Yi Yang; James S Hodges; Gregory J Beilman; Timothy L Pruett; Varvara A Kirchner; Ty B Dunn; Martin L Freeman; Guru Trikudanathan; Kristine E Mulier; Peggy Ptacek; Melena D Bellin Journal: Pancreas Date: 2020-07 Impact factor: 3.243